Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2223 13/01/2020 ocrelizumab (Ocrevus) Full

For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
SMC2121 10/12/2018 ocrelizumab (Ocrevus) Resubmission Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

No medicines have been found